40 Boxes: Save up to 30% on these new items!

Open menu

  • Video
  • Shop
  • Culture
  • Family
  • Wellness
  • Food
  • Living
  • Style
  • Travel
  • News
  • Book Club
  • GMA3: WYNTK
  • Newsletter
  • Privacy Policy
  • Your US State Privacy Rights
  • Children's Online Privacy Policy
  • Interest-Based Ads
  • Terms of Use
  • Do Not Sell My Info
  • Contact Us
  • © 2023 ABC News
  • Wellness

Pill shows promise in treating aggressive form of breast cancer

VIDEO: Drug shows promise in treating aggressive form of breast cancer
1:24
Drug shows promise in treating aggressive form of breast cancer
ABCNews.com
ByDr. Natalie S. Rosen
June 04, 2021, 3:52 pm

There is good news for women with a specific type of breast cancer, a new study has found.

A pill, known as Lynparza (olaparib) and produced by AstraZeneca, has been shown to potentially help tens of thousands of women each year with BRCA positive, HER2 negative disease, genetic markers that denote high-risk breast cancer. The combination of these genes is strongly associated with "triple-negative" breast cancer and is notoriously difficult to treat.

In 2021, an estimated 330,840 cases of breast cancer are expected to be diagnosed in the United States, according to the American Cancer Society. As 5-10% of breast cancer patients have the BRCA gene, nearly 33,000 diagnoses this year could be BRCA positive. BRCA positivity is more common in those with ovarian cancer, a strong family history of breast cancer, or are from certain ethnic groups.

"Typically, these women can be younger and there can be limited options," said Dr. Jennifer Ashton, ABC News chief medical correspondent and a board-certified OBGYN, who was not involved in the study.

While Lynparza is already approved to treat advanced, or metastatic, breast cancer, researchers found that it can now benefit those with earlier-stage disease and help them live longer.

The study, published Thursday in the New England Journal of Medicine, followed 1,836 patients with BRCA positive, HER2 negative disease who took Lynparza twice daily after completing traditional chemotherapy. Patients were followed over a three-year period and the results of the study were so promising the study was stopped earlier than planned.

Editor’s Picks

Identical twin sisters battle duplicate breast cancer diagnoses

  • Oct 06, 2020

New genes discovered that may increase risk for triple-negative breast cancer

  • Aug 06, 2018

Woman becomes sister’s surrogate after breast cancer diagnosis

  • Oct 28, 2019

Researchers found that the drug decreased patients' risk of recurrence of invasive breast cancer and increased the length of time of no signs or symptoms of cancer. At three years, 85.9% of patients who took Lynparza were alive without invasive breast cancer, compared with 77.1% of patients in the placebo group.

"The key here is progression-free survival and quality of life, not just about saving lives" said Ashton. "This drug can reduce the risk of recurrence or death by 42% over the placebo."

As for saving lives, the researchers showed that those who took Lynparza had fewer deaths than those who took the placebo.

The drug, while used in a new group of patients, is not a new drug. Termed a "PARP inhibitor," Lynparza remarkably stalls the ability of cancer cells to replicate. BRCA patients are unable to reverse this "stalling" and cancer cells die as a result.

"This drug is also used for women with ovarian cancer and it is being put into clinical trials for men with prostate cancer," said Ashton. "So there is a lot to watch out for."

The question of whether this drug will break the bank, is still up for debate. As Ashton notes, it has a "hefty price tag, about $14,000 a month. But that depends on what's covered by insurance."

As Lynparza benefits are dependent on BRCA positivity, it is now more important than ever to get screened for breast cancer and know of one's BRCA status earlier in the disease course.

"For women with these harmful mutations, [this drug] is a real game changer," Ashton said.

Natalie S. Rosen, M.D., is an internal medicine resident physician at The Johns Hopkins Hospital and a contributor to the ABC News Medical Unit.

Related Topics
  • Breast Cancer

Editor’s Picks

Identical twin sisters battle duplicate breast cancer diagnoses

  • Oct 06, 2020

New genes discovered that may increase risk for triple-negative breast cancer

  • Aug 06, 2018

Woman becomes sister’s surrogate after breast cancer diagnosis

  • Oct 28, 2019
Up Next in Wellness—

What Oprah Winfrey said about drugs used for weight loss like Ozempic, Mounjaro

September 21, 2023

Mom speaks out on daughter's death after water bead recall

September 21, 2023

FDA discusses using artificial wombs to help save preemie babies: What to know about the new technology

September 21, 2023

Morning exercisers tend to have healthier habits, which can help with weight loss, study finds

September 20, 2023

Up Next in Wellness—

What Oprah Winfrey said about drugs used for weight loss like Ozempic, Mounjaro

September 21, 2023

Mom speaks out on daughter's death after water bead recall

September 21, 2023

FDA discusses using artificial wombs to help save preemie babies: What to know about the new technology

September 21, 2023

Morning exercisers tend to have healthier habits, which can help with weight loss, study finds

September 20, 2023

The latest lifestyle and entertainment news and inspiration for how to live your best life - all from Good Morning America.
  • Contests
  • Terms of Use
  • Privacy Policy
  • Do Not Sell My Info
  • Children’s Online Privacy Policy
  • Advertise with us
  • Your US State Privacy Rights
  • Interest-Based Ads
  • About Nielsen Measurement
  • Press
  • Feedback
  • ABC News
  • ABC
  • All Videos
  • All Topics
  • Sitemap

© 2023 ABC News
  • Privacy Policy— 
  • Your US State Privacy Rights— 
  • Children's Online Privacy Policy— 
  • Interest-Based Ads— 
  • Terms of Use— 
  • Do Not Sell My Info— 
  • Contact Us— 

© 2023 ABC News